Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with locally advanced pancreatic cancer that cannot be removed by surgery, confirmed by a tissue or cell sample test, as classified by a standard medical staging system
• People aged between 18 and 80 years
• People who have at least one pancreatic cancer lesion that can be measured using standard imaging criteria
• People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning able to carry out normal daily activities with little or no restriction)
• People with a life expectancy of at least 3 months
• People whose blood counts, kidney function, and liver function fall within acceptable ranges on tests taken within 14 days before joining (confirm specific values with trial site)
• People who are able to provide tissue and blood samples for research purposes
• People who are able to understand the study details and sign a written consent form

Who may not be able to join:

• People who have had any other cancer in the past 5 years, except for certain localised cancers that have been fully treated and cured
• People with uncontrolled infections (such as active tuberculosis or hepatitis), uncontrolled whole-body illnesses, poorly controlled high blood pressure or diabetes, or serious health events in the past 6 months such as a heart attack, stroke, or significant heart rhythm problems
• People who have previously been treated with certain drugs that target specific parts of the immune system's T-cell response (confirm with trial site)
• People who have received radiation therapy within 2 weeks before joining the trial
• People with a known allergy to the study drug Ivonescimab or any of its ingredients
• People who are pregnant or currently breastfeeding
• People who are currently using or planning to use certain medications that strongly affect how the body processes drugs (known as strong CYP3A4/5 or CYP1A2 inducers or inhibitors — confirm specific medications with trial site)
• People who require certain blood-thinning tablets called oral vitamin K antagonists (such as full-dose warfarin), though low-dose warfarin and some other low-dose blood thinners may be permitted (confirm with trial site)
• People who have conditions that affect their ability to take oral medications, including a history of a hole or abnormal opening in the gut in the past 6 months, bowel obstruction, large bowel surgery, Crohn's disease, ulcerative colitis, or ongoing chronic diarrhoea

Important: Always verify eligibility with the trial site directly before applying.